Integrated Filing — IndAS



General information about company

Scrip Code 512161
NSE Symbol SECURKLOUD
MSEI Symbol NOTLISTED
ISIN INE650K01021
Name of company SECUREKLOUD TECHNOLOGIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Information Technology Services
Start date and time of board meeting 14-11-2025   11:00:00
End date and time of board meeting 14-11-2025   12:50:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 3,380.41 6,747.48
Other income 734.13 765.59
Total income 4,114.54 7,513.07
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 3,754.59 7,240.24
(e) Finance costs 204.22 390.11
(f) Depreciation, depletion and amortisation expense 62.44 94.97
(f) Other Expenses
1 Professional and Consultancy Charges 154.50 559.08
2 Travelling and conveyance 76.37 138.81
3 Rent 44.60 88.01
4 Fees, Rates and taxes 5.85 29.99
5 Sales and Marketing Expenses 613.30 884.84
6 Cloud Hosting and Communication Charges 225.39 462.97
7 Payments to auditors 0.67 12.83
8 Directors' Sitting Fees 0.35 1.25
9 Miscellaneous expenses 400.15 554.65
Total other expenses 1,521.18 2,732.43
Total expenses 5,542.43 10,457.75
3 Total profit before exceptional items and tax (1,427.89) (2,944.68)
4 Exceptional items 0.00 (13,949.39)
5 Total profit before tax (1,427.89) (16,894.07)
6 Tax expense
7 Current tax 82.40 82.40
8 Deferred tax 21.96 22.35
9 Total tax expenses 104.36 104.75
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (1,532.25) (16,998.82)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (1,532.25) (16,998.82)
17 Other comprehensive income net of taxes 3.17 3.17
18 Total Comprehensive Income for the period (1,529.08) (16,995.65)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (789.62) (8,760.10)
Total profit or loss, attributable to non-controlling interests (742.63) (8,238.72)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent (786.45) (8,756.93)
Total comprehensive income for the period attributable to owners of parent non-controlling interests (742.63) (8,238.72)
21 Details of equity share capital
Paid-up equity share capital 1,670.53 1,670.53
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.35 -26.21
Diluted earnings (loss) per share from continuing operations -2.35 -26.21
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.35 -26.21
Diluted earnings (loss) per share from continuing and discontinued operations -2.35 -26.21
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above consolidated financial results for the quarter and twelve months ended March 31, 2024, were reviewed by the audit committee and approved by the Board of Directors in its meeting held on May 30, 2024, in line with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The Statutory auditors of the Company have carried out an audit of the consolidated financial results and have issued an unmodified review opinion on the same in accordance with SEBI Circular No.CIR/CFD/CMD!/44/2019 dated March 29, 2019. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Ltd ('BSE') and is also available on the Company's website. The Consolidated financial results have been prepared in accordance with applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015, as amended, from time to time. 2. The Company operates in a single segment, i.e., Information and Technology Services and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments. 3. On February 27, 2025, Healthcare Triangle, Inc. (the Company) entered into securities purchase agreements with several institutional investors (the Investors') for the private placement of 36,190,485 units (each a, Unit'), with each Unit consisting of one share of the Company's common stock (Common Stock) and one pre-funded warrant (a Pre-Funded Warrant') to purchase one share of Common Stock, one Series A Warrant (a Series A Warrant') to purchase one share of common stock and one Series B Warrant (a Series B Warrant and together with the Series A Warrant, the Purchase Warrants') to purchase one shzre of Common Stock at an offering price of $0.42 per Unit (or $0.41999 per Unit in the case of Units that include pre-funded warrants), for gross proceeds of $15.2 million (excluding any related expenses and underwriting discounts). The voting interest of Mr Suresh Venkatachari, Chairman and CEO of SecureKloud Technologies Limited (SecureKloud), was 55.50% as of March 31, 2025. Further, on May 14, 2025, the Company filed a notice of effectiveness and issued up to 1,483,809,885 shares of common stock consequent to the conversion of Series A and Series B Warrants. On such issuance, the voting interest of Mr Suresh Venkatachari, decreased from 55.50% as of March 31, 2025, to 1.40% as of June 30, 2025. On August 1, 2025, the Company implemented a one-for-two-hundred-forty-nine (1:249) reverse stock split of all its issued and outstanding common shares. As a result of this corporate action, the voting interest of Mr. Suresh Venkatachari increased from 1.40% to 77.40%. Therefore, SecureKloud's Board is able to effectively control and direct the operations of the Company through Mr. Suresh Venkatachari. Accordingly, Healthcare Triangle, Inc. is consolidated into the financial statements of SecureKloud from Q2FY2026, in accordance with Ind AS 110 - Consolidated Financial Statements. 4. On June 16, 2025. Quantum Nexis, Inc, a 100% subsidiary of Healthcare Triangle, Inc announced the acquisitions of Niyama Healthcare, Inc and Ezovion Solutions for an aggregate consideration up to Five Million Seven Hundred Thousand Dollars ($5,700,000), payable $1,500,000 as upfront cash, $3,000,000 in common stocks and an earn-out of up to $1,200,000, payable in cash based on the achievement of certain agreed-upon financial targets during the first 12 months following the closing date. 5. The Company had presented consolidated results for the quarter ended June 30, 2025 without Healthcare Triangle, Inc. For the quarter ended September 30, 2025, the financial results have been consolidated including the results of operations of Healthcare Triangle, Inc in accordance with Ind AS 110. Accordingly, the results for the quarter ended June 30, 2025 have been restated on a consolidated basis to facilitate comparability. 6. The figures in the previous period financial results have been reclassified to confirm to the presentation of the current quarter financial results. These reclassifications have no effect on the previously reported net loss/profit.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 276.41
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 5,058.98
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 69.57
Total non-current financial assets 69.57
Deferred tax assets (net) 28.77
Other non-current assets 2.95
Total non-current assets 5,436.68
2 Current assets
Inventories 0.00
Current financial asset
Current investments 0.00
Trade receivables, current 4,334.09
Cash and cash equivalents 1,556.88
Bank balance other than cash and cash equivalents 0.00
Loans, current 0.00
Other current financial assets 168.41
Total current financial assets 6,059.38
Current tax assets (net) 116.77
Other current assets 416.43
Total current assets 6,592.58
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 12,029.26
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,309.49
Other equity (2,693.73)
Total equity attributable to owners of parent (384.24)
Non controlling interest (8,238.72)
Total equity (8,622.96)
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 3,567.88
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 98.76
Total non-current financial liabilities 3,666.64
Provisions, non-current 243.59
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 3,910.23
Current liabilities
Current financial liabilities
Borrowings, current 6,802.62
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 7.51
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 3,939.51
Total Trade payable 3,947.02
Other current financial liabilities 5,448.33
Total current financial liabilities 16,197.97
Other current liabilities 490.37
Provisions, current 53.65
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 16,741.99
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 20,652.22
Total equity and liabilites 12,029.26
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss (3.17) (3.17)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 3.17 3.17



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (16,894.07)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 390.11
Adjustments for decrease (increase) in inventories 0.00
Adjustments for decrease (increase) in trade receivables, current (2,367.24)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 27.29
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 6.87
Adjustments for other financial assets, current 579.28
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,495.12
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 94.97
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 44.53
Adjustments for other financial liabilities, current (10.31)
Adjustments for other financial liabilities, non-current 913.57
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (144.70)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (619.73)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 409.76
Net cash flows from (used in) operations (16,484.31)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 73.59
Other inflows (outflows) of cash 13,949.39
Net cash flows from (used in) operating activities (2,608.51)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 172.61
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,331.95)
Net cash flows from (used in) investing activities (1,504.56)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 106.49
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 390.11
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (496.60)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (4,609.67)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 185.17
Net increase (decrease) in cash and cash equivalents (4,424.50)
Cash and cash equivalents cash flow statement at beginning of period 5,981.38
Cash and cash equivalents cash flow statement at end of period 1,556.88